NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Anbio Biotechnology statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Market Cap | $470.52M | $197.05M |
| Enterprise Value | $458.62M | $106.56M |
| PE Ratio | 22.24 | 20.52 |
| PS Ratio | 54.42 | 3.93 |
| PB Ratio | 15.60 | 2.14 |
| P/TBV Ratio | 15.60 | 2.46 |
Enterprise value
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| EV / Sales | 53.04 | 2.69 |
| EV / EBITDA | 79.52 | 14.86 |
| EV / EBIT | 79.52 | 19.00 |
Income (trailing twelve months)
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Revenue | $8.65M | $57.94M |
| Gross Profit | $7.54M | $90.47M |
| Operating Income | $5.77M | -$21.44M |
| Pretax Income | $6.40M | -$14.45M |
| Net Income | $6.40M | -$22.46M |
| EBITDA | $5.77M | -$16.91M |
| EPS (Diluted) | $0.15 | -$0.83 |
Margins
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Gross Margin | 87.2% | 52.3% |
| Operating Margin | 66.7% | -44.5% |
| Pretax Margin | 74.1% | -13.0% |
| Profit Margin | 74.1% | -39.2% |
| EBITDA Margin | 66.7% | -31.3% |
Returns
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Return on Equity (ROE) | 27.0% | -53.1% |
| Return on Assets (ROA) | 26.0% | -41.0% |
| Return on Invested Capital (ROIC) | 48.7% | -32.0% |
| Return on Capital Employed (ROCE) | 19.1% | -37.8% |
Growth
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.64% | 6.01% |
| Net Income Growth (YoY) | 169.9% | -37.7% |
| EPS Growth (YoY) | 162.5% | -29.2% |
| Revenue Growth (3Y CAGR) | -28.4% | 2.25% |
| EPS Growth (3Y CAGR) | -98.9% | -0.17% |
Balance sheet
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.90M | $62.42M |
| Net Cash (Debt) | $11.90M | $15.68M |
| Net Cash Per Share | $0.08 | $0.65 |
| Equity (Book Value) | $30.16M | $48.79M |
| Book Value Per Share | $0.21 | $1.36 |
| Tangible Book Value | $30.16M | $23.06M |
| Working Capital | $30.16M | $75.77M |
Financial position
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Current Ratio | 344.31 | 3.30 |
| Quick Ratio | 177.12 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.74M | -$12.35M |
Efficiency
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Asset Turnover | 0.35 | 0.38 |
| Revenue Per Employee | $320.25K | $398.96K |
| Profits Per Employee | $237.17K | -$732.08K |
| Employee Count | 27 | 73 |
Dividends and yields
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Earnings Yield | 1.36% | -21.2% |
| Buyback Yield | -1.54% | -0.58% |
| Shareholder Yield | -1.54% | 0.00% |
Shares
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Shares Outstanding | 143,891,000 | 59,128,900 |
| Shares Change (YoY) | 3.27% | 11.1% |
| Float | 143,891,000 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
Taxes
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
| Effective Tax Rate | 0.00% | 20.6% |
Scores
| Measure | Anbio Biotechnology | Industry median |
|---|---|---|
| Graham Number | $0.83 | $17.36 |
| Graham Upside | -74.5% | -45.5% |
| Altman Z-Score | 3217.31 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Anbio Biotechnology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.